In a strategic shift confirmed by the German company, BI's Humira biosimilar Cyltezo will only be launched in the US while its version of Avastin has been abandoned altogether.
Boehringer Ingelheim GMBH has decided that its biosimilars business is going to focus on the US market and is pulling the plug on plans to develop them in the rest of the world.
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
CEO Vas Narasimhan urged European governments to spend more to support drug innovation during Novartis's first-quarter results call.
Two potentially first-in-class molecules signify Zai Lab’s renewed drive for the in-house discovery of drugs that it requires “to be innovative, differentiated and to have the potential to make a big difference for patients,” its global R&D head tells Scrip.
BridgeBio reported $36.7m in Q1 2025 sales of its ATTR-CM drug Attruby, tripling consensus forecasts. Vyndaquel-maker Pfizer acknowledged the product’s impact during the quarter.
